Cell signaling by endocannabinoids and their congeners: Questions of selectivity and other challenges

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 111-134

  Schmid, Harald H O ^a   Schmid, Patricia C ^a   Berdyshev, Evgueni V ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

2 Arachidonoylglycerol; Anandamide; Cell signaling; Metabolism; N acyl PE; N acylethanolamine

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 ARACHIDONOYLGLYCEROL; ACYLTRANSFERASE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; GINKGOLIDE B; PHOSPHODIESTERASE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; WORTMANNIN;

BIOSYNTHESIS; BRAIN REGION; CELL FUNCTION; CELL MEMBRANE TRANSPORT; CONFERENCE PAPER; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ION CURRENT; MAMMAL CELL; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ARACHIDONIC ACIDS; BIOLOGICAL TRANSPORT; CANNABINOIDS; CELL LINE; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 0037207094     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00157-3     Document Type: Conference Paper

References (205)

1. Adams I.B., Ryan W., Singer M., Thomas B.F., Compton D.R., Rasdan R.K., Martin B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273:1995;1172-1181.
2. Arai Y., Fukushima T., Shirao M., Yang X., Imai K. Sensitive determination of anandamide in rat brain utilizing a coupled-column HPLC with fluorimetric detection. Biomed. Chromatogr. 14:2000;118-124.
3. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:2001;300-302.
4. Basavarajappa B.S., Saito M., Cooper T.B., Hungund B.L. Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons. Biochim. Biophys. Acta. 1535:2000;78-86.
5. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
6. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoylglycerol cannabinoid activity. Eur. J. Pharmacol. 353:1998;23-31.
7. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids. 108:2000;169-190.
8. + cells. Biochem. J. 346:2000;369-374.
9. Berdyshev E.V., Schmid P.C., Krebsbach R.J., Hillard C.J., Huang C., Chen N., Dong Z., Schmid H.H.O. Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. Biochem. J. 360:2001;67-75.
10. Berdyshev E.V., Schmid P.C., Krebsbach R.J., Schmid H.H.O. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J. 15:2001;2171-2178.
11. Berglund B.A., Boring D.L., Wilken G.H., Makriyannis A., Howlett A.C., Lin S. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. Prostag. Leukotr. Essent. Fatty Acids. 59:1998;111-118. Erratum: Prostag. Leukotr. Essent. Fatty Acids 1999 60, 140.
12. Berrendero F., Sepe N., Ramos J.A., Di Marzo V., Fernandez-Ruiz J.J. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse. 33:1999;181-191.
13. Bifulco M., Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat. Med. 8:2002;547-550.
14. Bishop J.E., Hajra A.K. Specificity of reduction of fatty acids to long chain alcohols by rat brain microsomes. J. Neurochem. 30:1978;643-847.
15. Bisogno T., Ventriglia M., Milone A., Mosca M., Cimino G., Di Marzo V. Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim. Biophys. Acta. 1345:1997;338-348.
16. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272:1997;3315-3323.
17. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322:1997;671-677.
18. Bisogno T., Delton-Vandenbroucke I.D., Milone A., Lagarde M., Di Marzo V. Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch. Biochem. Biophys. 370:1999;300-307.
19. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256:1999;377-380.
20. Bisogno T., Melck D., De Petrocellis L., Di Marzo V. Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72:1999;2113-2119.
21. Bisogno T., Maccarrone M., De Petrocellis L., Jarrahian A., Finazzi-Agro A., Hillard C., Di Marzo V. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur. J. Biochem. 268:2001;1982-1989.
22. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60:2001;155-163.
23. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16:1996;3934-3942.
24. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidyl-ethanolamine, in rat brain. J. Neurosci. 17:1997;1226-1242.
25. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
26. Calignano A., La Rana G., Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol. 419:2001;191-198.
27. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit calcium current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:1992;231-232.
28. Chapman K.D. Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: signal transduction and membrane protection. Chem. Phys. Lipids. 108:2000;221-229.
29. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20:2001;7033-7040.
30. Clarke N.G., Hazlewood G.P., Dawson R.M. Novel lipids of Butyrivibrio spp. Chem. Phys. Lipids. 17:1976;222-232.
31. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
32. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA. 98:2001;9371-9376.
33. + channels. J. Physiol. 537:2001;793-800.
34. Das S.K., Paria B.C., Chakraborty I., Dey S.K. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc. Natl. Acad. Sci. USA. 92:1995;4332-4336.
35. Deadwyler S.A., Hampson R.E., Mu J., Whyte A., Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273:1995;734-743.
36. De Petrocellis L., Davis J.B., Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 506:2001;253-256.
37. Derkinderen P., Ledent C., Parmentier M., Girault J.A. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J. Neurochem. 77:2001;957-960.
38. Derocq J.M., Bouaboula M., Marchand J., Rinaldi-Carmona M., Segui M., Casellas P. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett. 425:1998;419-425.
39. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J. Biol. Chem. 270:1995;6030-6035.
40. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
41. Deutsch D.G., Glaser S.T., Howell J.M., Kunz J.S., Puffenbarger R.A., Hillard C.J., Abumrad N. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. 276:2001;6967-6973.
42. Deutsch D.G., Ueda N., Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostag. Leukotr. Essent. Fatty Acids. 66:2002;201-210.
43. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
44. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta. 1392:1998;153-175.
45. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.-C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
46. Di Marzo V., De Petrocellis L., Sepe N., Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316:1996;977-984.
47. Di Marzo V., Bisogno T., Sugiura T., Melck D., De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J. 331:1998;15-19.
48. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264:1999;258-267.
49. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14:2000;1432-1438.
50. Egertova M., Elphick M.R. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J. Comp. Neurol. 422:2000;159-171.
51. Epps D.E., Schmid P.C., Natarajan V., Schmid H.H.O. N-acylethanolamine accumulation in infarcted myocardium. Biochem. Biophys. Res. Commun. 90:1979;628-633.
52. Epps D.E., Natarajan V., Schmid P.C., Schmid H.H.O. Accumulation of N-acylethanolamine glycerophospholipids in infarcted myocardium. Biochim. Biophys. Acta. 618:1980;420-430.
53. Farooqui A.A., Anderson D.K., Flynn C., Bradel E., Means E.D., Horrocks L.A. Stimulation of mono- and di-acylglycerol lipase activities by bradykinin in neural cultures. Biochem. Biophys. Res. Commun. 166:1990;1001-1009.
54. Farooqui A.A., Anderson D.K., Horrocks L.A. Effect of glutamate and its analogs on diacylglycerol and monoacylglycerol lipase activities of neuron-enriched cultures. Brain Res. 604:1993;180-184.
55. Farooqui A.A., Horrocks L.A., Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids. 106:2000;1-29.
56. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48:1995;443-450.
57. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
58. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513:2002;294-298.
59. Fowler C.J., Jacobsson S.O.P. Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide-targets for drug development? Prostag. Leukotr. Essent. Fatty Acids. 66:2002;193-200.
60. Gallily R., Breuer A., Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur. J. Pharmacol. 406:2000;R5-R7.
61. Gammon C.M., Allen A.C., Morell P. Bradykinin stimulates phosphoinositide hydrolysis and mobilization of arachidonic acid in dorsal root ganglion neurons. J. Neurochem. 53:1989;95-101.
62. 2+ channel current. Am. J. Physiol. 276:1999;H2085-H2093.
63. Gerdeman G.L., Ronesi J., Lovinger D.M. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5:2002;446-451.
64. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2:1999;358-363.
65. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., Hipkin R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57:2000;1045-1050.
66. Goparaju S.K., Ueda N., Yamaguchi H., Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 422:1998;69-73.
67. Goparaju S.K., Kurahashi Y., Suzuki H., Ueda N., Yamamoto S. Anandamide amidohydrolase of porcine brain: cDNA cloning, functional expression and site-directed mutagenesis(1). Biochim. Biophys. Acta. 1441:1999;77-84.
68. Gray G.M. Phosphatidyl-(N-acyl)-ethanolamine. A lipid component of mammalian epidermis. Biochim. Biophys. Acta. 431:1976;1-8.
69. Gulaya N.M., Melnik A.A., Balkov D.I., Volkov G.L., Vysotskiy M.V., Vaskovsky V.E. The effect of long-chain N-acylethanolamines on some membrane-associated functions of neuroblastoma C1300 N18 cells. Biochim. Biophys. Acta. 1152:1993;280-288.
70. Hajos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106:2001;1-4.
71. Hajra A.K. Biosynthesis of O-alkylglycerol ether lipids. Mangold H.K., Paltauf F. Ether Lipids Biochemical and Biomedical Aspects. 1983;85-106 Academic Press.
72. Hansen H.H., Hansen S.H., Schousboe A., Hansen H.S. Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons. J. Neurochem. 75:2000;861-871.
73. Hansen H.S., Moesgaard B., Hansen H.H., Petersen G. N-acylethanolamines and precursor phospholipids - relation to cell injury. Chem. Phys. Lipids. 108:2000;135-150.
74. Hansen H.H., Ikonomidou C., Bittigau P., Hansen S.H., Hansen H.S. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem. 76:2001;39-46.
75. Hansen H.H., Schmid P.C., Bittigau P., Lastres-Becker I., Berrendero F., Manzanares J., Ikonomidou C., Schmid H.H.O., Fernandez-Ruiz J.J., Hansen H.S. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78:2001;1415-1427.
76. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
77. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;3662-3665.
78. Hasegawa-Sasaki H. Early changes in inositol lipids and their metabolites induced by platelet-derived growth factor in quiescent Swiss mouse 3T3 cells. Biochem. J. 232:1985;99-109.
79. Hillard C.J. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat. 61:2000;3-18.
80. Hillard C.J., Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids. 108:2000;123-134.
81. Hillard C.J., Wilkison D.M., Edgemond W.S., Campbell W.B. Characterization of the kinetics and distribution of N-arachidonyl-ethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta. 1257:1995;249-256.
82. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69:1997;631-638.
83. 1). J. Pharmacol. Exp. Ther. 289:1999;1427-1433.
84. Howlett A.C., Mukhopadhyay. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids. 108:2000;53-70.
85. Huang S.M., Strangman N.M., Walker J.M. Liquid chromatographic-mass spectrometric measurement of the endogenous cannabinoid 2-arachidonylglycerol in the spinal cord and peripheral nervous system. Zhongguo Yao Li Xue Bao. 20:1999;1098-1102.
86. Huang C.C., Lo S.W., Hsu K.S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 532:2001;731-748.
87. Irving A.J., Coutts A.A., Harvey J., Rae M.G., Mackie K., Bewick G.S., Pertwee R.G. Functional expression of cell surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience. 98:2000;253-262.
88. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
89. Jarrahian A., Manna S., Edgemond W.S., Campbell W.B., Hillard C.J. Structure-activity relationships among N-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter. J. Neurochem. 74:2000;2597-2606.
90. Kanoh H., Iwata T., Ono T., Suzuki T. Immunological characterization of sn-1,2-diacylglycerol and sn-2-monoacylglycerol kinase from pig brain. J. Biol. Chem. 261:1986;5597-5602.
91. Katayama K., Ueda N., Katoh I., Yamamoto S. Equilibrium in the hydrolysis and synthesis of cannabimimetic anandamide demonstrated by a purified enzyme. Biochim. Biophys. Acta. 1440:1999;205-214.
92. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., Freund T.F. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 21:2001;9506-9518.
93. Kempe K., Hsu F.-F., Bohrer A., Turk J. Isotope dilution mass spectrometric measurements indicate that arachidonoylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. J. Biol. Chem. 271:1996;17287-17295.
94. Kobayashi Y., Arai S., Waku K., Sugiura T. Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells. J. Biochem. 129:2001;665-669.
95. Koga D., Santa T., Fukushima T., Homma H., Imai K. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J. Chromatogr. B Biomed. Sci. Appl. 690:1997;7-13.
96. Kondo S., Sugiura T., Kodaka T., Kudo N., Waku K., Tokumura A. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. Arch. Biochem. Biophys. 354:1998;303-310.
97. 2+-dependent and -independent mechanisms. FEBS Lett. 429:1998;152-156.
98. Konrad R.J., Major C.D., Wolf B.A. Diacylglycerol hydrolysis to arachidonic acid is necessary for insulin secretion from isolated pancreatic islets: sequential actions of diacylglycerol and monoacylglycerol lipases. Biochemistry. 33:1994;13284-13294.
99. Kozak K.R., Rowlinson S.W., Marnett L.J. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 275:2000;33744-33749.
100. Kozak K.R., Gupta R.A., Moody J.S., Ji C., Boeglin W.E., DuBois R.N., Brash A.R., Marnett L.J. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor α agonist. J. Biol. Chem. 277:2002;23278-23286.
101. Kreitzer A.C., Regehr W.G. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J. Neurosci. 21:2001;RC174.
102. Kreitzer A.C., Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 29:2001;717-727.
103. Kurahashi Y., Ueda N., Suzuki H., Suzuki M., Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochem. Biophys. Res. Commun. 237:1997;512-515.
104. Kuwae T., Shiota Y., Schmid P.C., Krebsbach R., Schmid H.H.O. Biosynthesis and turnover of anandamide and other N-acylethanolamines in peritoneal macrophages. FEBS Lett. 459:1999;123-127.
105. Lambert D.M., Vandevoorde S., Diependaele G., Govaerts S.J., Robert A.R. Anticonvulsant activity of N-palmitylethanolamide, a putative endocannabinoid, in mice. Epilepsia. 42:2001;321-327.
106. Lang W., Qin C., Hill W.A., Lin S., Khanolkar A.D., Makriyannis A. High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. Anal. Biochem. 238:1996;40-45.
107. Liu J., Gao B., Mirshahi F., Sanyal A.J., Khanolkar A.D., Makriyannis A., Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346:2000;835-840.
108. Liu J., Harvey-White J., Batkai S., Gao B., Kunos G. Role of NFκB and p44/42 pathways in lipopolysaccharide-induced increase of anandamide synthesis in RAW264.7 macrophages. Pharmacologist 44/2. 1:(Suppl.):2002;A112.
109. Liu Q., Tonai T., Ueda N. Activation of N-acylethanolamine-releasing phospholipase D by polyamines. Chem. Phys. Lipids. 115:2002;77-84.
110. Maccarrone M., Attina M., Cartoni A., Bari M., Finazzi-Agro A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J. Neurochem. 76:2001;594-601.
111. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
112. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:1995;6552-6561.
113. Maejima T., Hashimoto K., Yoshida T., Aiba A., Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron. 31:2001;463-475.
114. + channel TASK-1. EMBO J. 20:2001;47-54.
115. Matias I., Bisogno T., Melck D., Vandenbulcke F., Verger-Bocquet M., De Petrocellis L., Sergheraert C., Breton C., Di Marzo V., Salzet M. Evidence for an endocannabinoid system in the central nervous system of the leech Hirudo medicinalis. Brain Res. Mol. Brain Res. 87:2001;145-159.
116. McAllister S.D., Griffin G., Satin L.S., Abood M.E. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J. Pharmacol. Exp. Ther. 291:1999;618-626.
117. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
118. Mechoulam R., Fride E., Hanus L., Sheskin T., Bisogno T., Di Marzo V., Bayewitch M., Vogel Z. Anandamide may mediate sleep induction. Nature. 389:1997;25-26.
119. Mechoulam R., Fride E., Ben-Shabat S., Meiri U., Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur. J. Pharmacol. 362:1998;R1-R3.
120. Misner D.L., Sullivan J.M. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J. Neurosci. 19:1999;6795-6805.
121. 31P NMR and enzyme activity study. J. Lipid Res. 41:2000;985-990.
122. Moldrich G., Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides. 21:2000;1735-1742.
123. Moody J.S., Kozak K.R., Ji C., Marnett L.J. Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. Biochemistry. 40:2001;861-866.
124. Natarajan V., Schmid H.H.O. Substrate specificities in ether lipid biosynthesis. Metabolism of polyunsaturated fatty acids and alcohols by rat brain microsomes. Biochem. Biophys. Res. Commun. 79:1977;411-416.
125. Natarajan V., Reddy P.V., Schmid P.C., Schmid H.H.O. N-Acylation of ethanolamine phospholipids in canine myocardium. Biochim. Biophys. Acta. 712:1982;342-355.
126. Natarajan V., Schmid P.C., Reddy P.V., Zuzarte-Augustin M.L., Schmid H.H.O. Biosynthesis of N-acylethanolamine phospholipids by dog brain preparations. J. Neurochem. 41:1983;1303-1312.
127. Natarajan V., Schmid P.C., Reddy P.V., Schmid H.H.O. Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J. Neurochem. 42:1984;1613-1619.
128. Natarajan V., Schmid P.C., Reddy P.V., Zuzarte-Augustin M.L., Schmid H.H.O. Occurrence of N-acylethanolamine phospholipids in fish brain and spinal cord. Biochim. Biophys. Acta. 835:1985;426-433.
129. Natarajan V., Schmid P.C., Schmid H.H.O. N-Acylethanolamine phospholipid metabolism in normal and ischemic rat brain. Biochim. Biophys. Acta. 878:1986;32-41.
130. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29:2001;729-738.
131. Ohno-Shosaku T., Tsubokawa H., Mizushima I., Yoneda N., Zimmer A., Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 22:2002;3864-3872.
132. Ong W.Y., Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience. 92:1999;1177-1191.
133. Ouyang Y., Hwang S.G., Han S.H., Kaminski N.E. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol. Pharmacol. 53:1998;676-683.
134. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., Stalla G.K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 86:2001;2687-2696.
135. Paria B.C., Song H., Wang X., Schmid P.C., Krebsbach R.J., Schmid H.H.O., Bonner T.I., Zimmer A., Dey S.K. Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. J. Biol. Chem. 276:2001;20523-20528.
136. Patricelli M.P., Cravatt B.F. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochemistry. 38:1999;14125-14130.
137. Patricelli M.P., Lovato M.A., Cravatt B.F. Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties. Biochemistry. 38:1999;9804-9812.
138. Patricelli M.P., Cravatt B.F. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vitam. Horm. 62:2001;95-131.
139. Patricelli M.P., Lashuel H.A., Giang D.K., Kelly J.W., Cravatt B.F. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry. 37:1998;15177-15187.
140. Petersen G., Hansen H.S. N-Acylphosphatidylethanolamine-hydrolysing phospholipase D lacks the ability to transphosphatidylate. FEBS Lett. 455:1999;41-44.
141. Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., Cabral G.A. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res. 51:1998;391-402.
142. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA. 96:1999;5802-5807.
143. + channels. Neuropharmacology. 35:1996;983-991.
144. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301:2002;1020-1024.
145. Prescott S.M., Majerus P.W. Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J. Biol. Chem. 258:1983;764-769.
146. Qin C., Lin S., Lang W., Goutopoulos A., Pavlopoulos S., Mauri F., Makriyannis A. Determination of anandamide amidase activity using ultraviolet-active amine derivatives and reverse-phase high-performance liquid chromatography. Anal. Biochem. 261:1998;8-15.
147. Reddy P.V., Natarajan V., Schmid P.C., Schmid H.H.O. N-acylation of dog heart ethanolamine phospholipids by transacylase activity. Biochim. Biophys. Acta. 750:1983;472-480.
148. Reddy P.V., Schmid P.C., Natarajan V., Schmid H.H.O. The role of cardiolipin as an acyl donor in N-acylethanolamine phospholipid biosynthesis. Biochim. Biophys. Acta. 751:1983;241-246.
149. Reddy P.V., Schmid P.C., Natarajan V., Muramatsu T., Schmid H.H.O. Properties of canine myocardial phosphatidylethanolamine N-acyltransferase. Biochim. Biophys. Acta. 795:1984;130-136.
150. Reggio P.H., Traore H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem. Phys. Lipids. 108:2000;15-35.
151. Robbe D., Kopf M., Remaury A., Bockaert J., Manzoni O.J. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. USA. 99:2002;8384-8388.
152. Rodriguez J.J., Mackie K., Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J. Neurosci. Feb 1;21:(3):2001;823-833.
153. Rueda D., Galve-Roperh I., Haro A., Guzman M. The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. 58:2000;814-820.
154. Savinainen J.R., Jarvinen T., Laine K., Laitinen J.T. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol. 134:2001;664-672.
155. Schmid H.H.O. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem. Phys. Lipids. 8:2000;71-87.
156. Schmid H.H.O., Berdyshev E.V. Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides. Metabolism and function. Prostag. Leukotr. Essent. Fatty Acids. 66:2002;363-376.
157. Schmid P.C., Schmid H.H.O. N-Acylation of ethanolamine phospholipids by acyl transfer does not involve hydrolysis. Biochim. Biophys. Acta. 922:1987;398-400.
158. Schmid P.C., Reddy P.V., Natarajan V., Schmid H.H.O. Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem. 258:1983;9302-9306.
159. Schmid P.C., Zuzarte-Augustin M.L., Schmid H.H.O. Properties of rat liver N-acylethanolamine amidohydrolase. J. Biol. Chem. 260:1985;14145-14149.
160. Schmid H.H.O., Schmid P.C., Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog. Lipid Res. 29:1990;1-43.
161. Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maassen J.L., Schmid H.H.O. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375:1995;117-120. Corrigendum, 1996, 385, 125-126.
162. Schmid P.C., Kuwae T., Krebsbach R.J., Schmid H.H.O. Anandamide and other N-acylethanolamines in mouse peritoneal macrophages. Chem. Phys. Lipids. 87:1997;103-110.
163. Schmid P.C., Paria B.C., Krebsbach R.J., Schmid H.H.O., Dey S.K. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc. Natl. Acad. Sci. USA. 94:1997;4188-4192.
164. Schmid P.C., Schwindenhammer D., Krebsbach R.J., Schmid H.H.O. Alternative pathways of anandamide biosynthesis in rat testes. Chem. Phys. Lipids. 92:1998;27-35.
165. Schmid P.C., Schwartz K.D., Smith C.N., Krebsbach R.J., Berdyshev E.V., Schmid H.H.O. A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. Chem. Phys. Lipids. 104:2000;185-191.
166. Schmid P.C., Wold L.E., Krebsbach R.J., Berdyshev E.V., Schmid H.H.O. Anandamide and other N-acylethanolamines in human tumors. Lipids. 37:2002;907-912.
167. Sepe N., De Petrocellis L., Montanaro F., Cimino G., Di Marzo V. Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. Biochim. Biophys. Acta. 1389:1998;101-111.
168. Shim Y.H., Lin C.H., Strickland K.P. The purification and properties of monoacylglycerol kinase from bovine brain. Biochem. Cell Biol. 67:1989;233-241.
169. Simpson C.M., Itabe H., Reynolds C.N., King W.C., Glomset J.A. Swiss 3T3 cells preferentially incorporate sn-2-arachidonoyl monoacylglycerol into sn-1-stearoyl-2-arachidonoyl phosphatidylinositol. J. Biol. Chem. 266:1991;15902-15909.
170. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
171. Smart D., Jonsson K.O., Vandevoorde S., Lambert D.M., Fowler C.J. 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br. J. Pharmacol. 136:2002;452-458.
172. Stella N., Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425:2001;189-196.
173. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
174. Su K.L., Schmid H.H.O. Metabolism of long-chain polyunsaturated alcohols in myelinating brain. J. Lipid Res. 13:1972;452-457.
175. Sugiura T., Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem. Phys. Lipids. 108:2000;89-106.
176. Sugiura T., Itoh K., Waku K., Hanahan D.J. Biological activities of N-acylethanolamine and N-acylethanolamine phosphate analogues (in Japanese). Proc. Jpn Conf. Biochem. Lipids. 36:1994;71-74.
177. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
178. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., Ishima Y., Waku K. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamide, an endogenous cannabinoid receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240:1996;53-62.
179. 2+-dependent transacylase and phosphodiesterase activities. Biochem. Biophys. Res. Commun. 218:1996;113-117.
180. 2+ in neuroblastoma×glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 229:1996;58-64.
181. 2+ transient in NG108-15 cells. J. Biochem. 122:1997;890-895.
182. Sugiura T., Kodaka T., Kondo S., Tonegawa T., Nakane S., Kishimoto S., Yamashita A., Waku K. Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma×glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 233:1997;207-210.
183. Sugiura T., Kodaka T., Nakane S., Kishimoto S., Kondo S., Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem. Biophys. Res. Commun. 243:1998;838-843.
184. Sugiura T., Kodaka T., Nakane S., Miyashita T., Kondo S., Suhara Y., Takayama H., Waku K., Seki C., Baba N., Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 274:1999;2794-2801.
185. Sugiura T., Nakane S., Kishimoto S., Waku K., Yoshioka Y., Tokumura A., Hanahan D.J. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim. Biophys. Acta. 1440:1999;194-204.
186. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T., Suhara Y., Takayama H., Waku K. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275:2000;605-612.
187. Sugiura T., Yoshinaga N., Kondo S., Waku K., Ishima Y. Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem. Biophys. Res. Commun. 271:2000;654-658.
188. Sugiura T., Yoshinaga N., Waku K. Rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation. Neurosci. Lett. 297:2001;175-178.
189. Sugiura T., Kobayashi S., Oka S., Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostag. Leukotr. Ess. 66:2002;173-192.
190. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:1997;43-50.
191. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 270:1995;23823-23827.
192. Ueda N., Puffenbarger R.A., Yamamoto S., Deutsch D.G. The fatty acid amide hydrolase (FAAH). Chem. Phys. Lipids. 108:2000;107-121.
193. Ueda N., Liu Q., Yamanaka K. Marked activation of the N-acylphosphatidylethanolamine-hydrolyzing phosphodiesterase by divalent cations. Biochim. Biophys. Acta. 1532:2001;121-127.
194. Ueda N., Yamanaka K., Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 276:2001;35552-35557.
195. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12:1998;1035-1044.
196. Varma N., Carlson G.C., Ledent C., Alger B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21:2001;1-5.
197. Waite M. The PLD superfamily: insights into catalysis. Biochim. Biophys. Acta. 1439:1999;187-197.
198. Walter L., Franklin A., Witting A., Moller T., Stella N. Astrocytes in culture produce anandamide and other acylethanolamides. J. Biol. Chem. 277:2002;20869-20876.
199. Wang Y., Liu Y., Ito Y., Hashiguchi T., Kitajima I., Yamakuchi M., Shimizu H., Matsuo S., Imaizumi H., Maruyama I. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal. Biochem. 294:2001;73-82.
200. Wartmann M., Campbell D., Subramanian A., Burstein S.H., Davis R.J. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett. 359:1995;133-136.
201. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410:2001;588-592. Erratum: Nature 2001, 411, 974.
202. Wilson R.I., Kunos G., Nicoll R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron. 31:2001;453-462.
203. Yang H.Y., Karoum F., Felder C., Badger H., Wang T.C., Markey S.P. GC/MS analysis of anandamide and quantification of N-arachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat. J. Neurochem. 72:1999;1959-1968.
204. Yoshida T., Hashimoto K., Zimmer A., Maejima T., Araishi K., Kano M. The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. J. Neurosci. 22:2002;1690-1697.
205. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.